Financial reports
10-K
2023 FY
Annual report
27 Mar 24
10-Q
2023 Q3
Quarterly report
26 Oct 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
30 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
10-K
2021 FY
Annual report
31 Mar 22
Current reports
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
26 Mar 24
8-K
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
25 Mar 24
8-K
Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
21 Mar 24
8-K
Results of Operations and Financial Condition
14 Feb 24
8-K/A
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 Jan 24
8-K/A
Completion of Acquisition or Disposition of Assets
12 Jan 24
8-K
Departure of Directors or Certain Officers
15 Dec 23
8-K
Regulation FD Disclosure
6 Dec 23
8-K
Regulation FD Disclosure
14 Nov 23
8-K
Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting
13 Nov 23
Registration and prospectus
S-8
Registration of securities for employees
27 Mar 24
RW
Registration withdrawal request
29 Nov 23
D
$5.00 mm in equity / options, sold $5.00 mm, 1 investor
13 Nov 23
S-3
Shelf registration
9 Nov 23
424B3
Prospectus supplement
1 Nov 23
S-8
Registration of securities for employees
30 Oct 23
424B3
Prospectus supplement
27 Oct 23
S-3/A
Shelf registration (amended)
24 Oct 23
S-3/A
Shelf registration (amended)
13 Oct 23
S-3
Shelf registration
24 Jul 23
Proxies
PRE 14A
Preliminary proxy
19 Apr 24
DEFM14A
Proxy related to merger
20 Jul 23
PRER14A
Preliminary revised proxy
12 Jul 23
PRER14A
Preliminary revised proxy
26 Jun 23
DEFA14A
Additional proxy soliciting materials
20 Jun 23
PRER14A
Preliminary revised proxy
15 May 23
DEFA14A
Additional proxy soliciting materials
5 May 23
DEFA14A
Additional proxy soliciting materials
7 Apr 23
PREM14A
Preliminary proxy related to merger
30 Mar 23
DEFA14A
Additional proxy soliciting materials
30 Mar 23
Other
EFFECT
Notice of effectiveness
30 Oct 23
CORRESP
Correspondence with SEC
24 Oct 23
CORRESP
Correspondence with SEC
13 Oct 23
UPLOAD
Letter from SEC
3 Aug 23
UPLOAD
Letter from SEC
20 Jul 23
CORRESP
Correspondence with SEC
12 Jul 23
UPLOAD
Letter from SEC
10 Jul 23
CORRESP
Correspondence with SEC
26 Jun 23
UPLOAD
Letter from SEC
31 May 23
CORRESP
Correspondence with SEC
15 May 23
Ownership
144
Notice of proposed sale of securities
9 Apr 24
144
Notice of proposed sale of securities
8 Apr 24
144
Notice of proposed sale of securities
5 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
144
Notice of proposed sale of securities
3 Apr 24
4
NASSIM USMAN
3 Apr 24
144
Notice of proposed sale of securities
2 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
Rodney L Nussbaum
21 Mar 24
3
Rodney L Nussbaum
21 Mar 24